Case of acute hepatitis E with concomitant signs of autoimmunity

Catarina Lima Vieira, Cilénia Baldaia, Narcisa Fatela, Fernando Ramalho, Carlos Cardoso

Catarina Lima Vieira, Cilénia Baldaia, Narcisa Fatela, Fernando Ramalho, Carlos Cardoso, Department of Gastroenterology and Hepatology, Hospital Santa Maria, Avenida Professor Egas Moniz, 1649-035 Lisbon, Portugal
Catarina Lima Vieira, Cilénia Baldaia, Narcisa Fatela, Fernando Ramalho, Carlos Cardoso, Department of Virology, Laboratory Dr. Joaquim Chaves, 1500-486 Lisbon, Portugal

Author contributions: All the authors contributed equally to this work.

Correspondence to: Catarina Lima Vieira, MD, Department of Gastroenterology and Hepatology, Hospital Santa Maria, Avenida Professor Egas Moniz 9, 1649-035 Lisbon, Portugal. rinacilv@gmail.com
Telephone: +351-918839182 Fax: +351-217802775
Received: May 13, 2012 Revised: October 28, 2012 Accepted: November 17, 2012 Published online: March 27, 2013

Abstract

Sporadic cases of acute viral hepatitis E have been described in developed countries, despite the more common occurrence in endemic areas and developing countries. We present the case of a 58 years old Portuguese female, with no epidemiological relevant factors, admitted with acute hepatitis with positive anti-nuclear antibodies, anti-smooth muscle antibody and high serum gamma globulin (> 1.5 fold increase). Serologies for hepatitis A virus, hepatitis B virus, hepatitis C virus, Epstein-Barr virus, cytomegalovirus, hereditary sensory neuropathy and varicella zoster virus were negative. Liver biopsy histology revealed changes compatible with autoimmune hepatitis. Prednisolone and azathioprine was started. She tested positive for immunoglobulin M anti hepatitis E virus (HEV) with detectable viremia by reverse transcription polymerase chain reaction (RT-PCR) technique. HEV-RNA was confirmed through RT-PCR in a liver specimen, establishing the diagnosis of acute hepatitis E. Immunosuppression was stopped. She clinically improved, with resolution of laboratory abnormalities. Therefore, we confirmed acute hepatitis E as the diagnosis. We review the literature to elucidate about HEV infection and its autoimmune effects.

© 2013 Baishideng. All rights reserved.

Key words: Hepatitis; Hepatitis E; Autoimmune; Ribavirin

Vieira CL, Baldaia C, Fatela N, Ramalho F, Cardoso C. Case of acute hepatitis E with concomitant signs of autoimmunity. World J Hepatol 2013; 5(3): 152-155 Available from: URL: http://www.wjgnet.com/1948-5182/full/v5/i3/152.htm DOI: http://dx.doi.org/10.4254/wjh.v5.i3.152

INTRODUCTION

Acute hepatitis can result from a variety of etiologies, which include viral [hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus, hepatitis E virus (HEV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus, varicella zoster virus] etiologies, autoimmune hepatitis (AIH), non alcoholic steatohepatitis, toxins and metabolic disorders, like Wilson's disease. Epidemiology is an important factor. HEV, an enterically transmitted virus, occurs mainly in developing countries. Swine seem to function as a reservoir for HEV. The majority of cases have been reported in pregnant women, immunosuppressed patients and in those with contact with swine. However, recent data suggest that the HEV could be more widespread than previously thought, with more sensitive tests increasing detection rates[1]. Cases of sporadic HEV have also been described[10]. To diagnose AIH using the International Autoimmune Hepatitis Group (IAIHG) score for AIH, the exclusion of other etiologies is required before classifying AIH as probable or definitive[12]. When using the recent simplified criteria for AIH[11], the exclusion of viral etiology is one of the 4 criteria, together with liver histology, gamma globulin level and antibody markers [anti-nuclear antibodies (ANA), anti-smooth muscle antibody
March 27, 2013

**CASE REPORT**

A 58 years old female Caucasian patient was admitted to our hospital with a history of progressive fatigue and anorexia over 6 wk and markedly increased liver enzymes. She had a past medical history of rheumatic fever, with normal cardiac function, nephrolithiasis, diabetes mellitus, major depression and recent traumatic fracture of the wrist (3 mo before), medicated with venlafaxine, mirtazapine, lisinopril, nevirivol, bromazeepam and diolofenac (last taken 3 mo before admission and maximum 1 per day). She had no history of contact with animals or previous stays in regions endemic for hepatotropic viruses, and mentioned regular swine meat ingestion. There was no history of immunosuppressive therapy. On examination, she was apyretic and subicteric. There was no evidence of clinical encephalopathy, pruritis, dermatological lesions, hemorrhagic dyscrasia or abdominal pain. Laboratory analysis showed altered liver enzymes with aspartate aminotransferase (AST) 2088 IU/L (0-34); alanine aminotransferase (ALT) 2638 IU/L (10-49); alkaline phosphatase 233 IU/L (45-129); gamma-glutamyl transpeptidase 197 IU/L (< 38); total bilirubin 3.17 mg/dL (< 1.0); prothrombin time 13.7/11.6 s; V factor 122% (50-100); VCr factor 40% (70-130); gamma globulin 3.15 g/dL (0.68-1.60); and immunoglobulin G (IgG) 3850 mg/dL (< 1.0); prothrombin time 13.7/11.6 s; V factor 122% (50-100); VCr factor 40% (70-130); gamma globulin 3.15 g/dL (0.68-1.60); and immunoglobulin G (IgG) 3850 mg/dL (700-1600). The serological tests for autoimmune hepatitis revealed positive ANA (titer 1:320 with cytoplasmic pattern); anti-DsDNA (824 IU/mL; < 200); ASMA positive, thyroid auto-antibodies, type anti-thyroid peroxidase antibody (243 IU/mL; < 200); with negative tests for anti-liver kidney microsomal, anti-mycocardial antibody, SSA, single-strand binding protein, ribonucleoprotein, HS70 and J01. Viral serology was negative for HAV [IgM (+); IgG (−), EBV [IgM (−); IgG (+)], CMV [IgM (−); IgG (−)], HBV (AgHBs, AgHbe, AcHBe, antiHBs), negative anti-HCV with undetectable RNA of HCV and HIV antigens types 1 and 2 both negative. Serological tests for Coxiella burnetii and leptospirosis were negative. Tests for iron and copper metabolic disorders were negative. Laboratory tests showed normal alpha1 antitrypsin complement and IgG4 levels. Thyroid function tests were also normal. The abdominal Doppler ultrasound was normal. A percutaneous liver biopsy was performed and compatible with autoimmune hepatitis, revealing intense interface hepatitis, with lymphoplasmacytic portal, septal and acinar infiltrate with focal hepatocellular necrosis and areas of periportal fibrosis. The patient did not have an epidemiological history favoring HEV and, prior to knowing its results, the IAIHG pre-treatment score was 14 points considering a negative viral study [female sex (+2); ALP/AST < 1.5 (+2); IgG > 2 × normal upper limit (+3); ANA > 1.80 (+3); negative AMA; alcohol intake < 25 g/d (+3); hepatotoxics drugs present (-4); interface hepatitis (+5)]. As the patient met the absolute criteria with AST, ALT > 10 × the upper limit of normal, a diagnosis of type 1 AIH was considered and therapy was started on day 7\(^{\text{1}}\). Retrospectively, we realized that both the AST and ALT levels (Figure 1) were already slowly decreasing 24 h before the immunosuppressive therapy was started. After one week on prednisolone 30 mg/d and azathioprine 50 mg/d, there was a significant reduction in the laboratory values: AST 245 U/L; ALT 835 U/L; ALP 148 U/L; GGT 214 U/L; total bilirubin 1.06 mg/dI; prothrombin time 12.5/11.6 (Figure 1, day 12). She was discharged with the combined immunosuppressive treatment for AIH. There was a progressive improvement of symptoms. One month after discharge, she was asymptomatic with normal total bilirubin (0.67 mg/dL) and gamma globulin (1.25 g/dL) but AST and ALT were still > 2 × the upper limit (AST 94 U/L; ALT 158 U/L). The results of serological tests for HEV were obtained after the patient was discharged. The patient had positive IgM serology for HEV and negative serology for IgG. The tests were performed using the enzyme-linked immunosorbent assay method by MP Biomedicals (IgM determination: sensitivity 95.8%; specificity 97.6%). Positive viremia was detected by real time polymerase chain reaction (PCR) but not quantified. This technique has

![Figure 1 Evolution of aspartate aminotransferase and alanine aminotransferase during the hospitalization period. Introduction of immunosuppression was as shown in the figure at day 7, when aspartate aminotransferase (AST) levels were already lowering. ALT: Alanine aminotransferase.](Image 337x494 to 494x640)
**Table 1** The evolution of antibodies

| Day after admission | ANA; anti DsDNA titer (UI/mL) |
|---------------------|-------------------------------|
| 0                   | 1/320; 840                   |
| 30                  | 1/160, 520                   |
| 90                  | Negative; < 200              |
| 180                 | Negative; < 200              |

ANA: Anti-nuclear antibodies.

Figure 2 Electrophoresis with agarose gel 2%. Reverse transcription polymerase chain reaction (RT-PCR) for hepatitis E virus (HEV) RNA from the liver specimen was performed using a First Strand cDNA synthesis kit for RT-PCR from Roche Diagnostics (Indianapolis, United States) according to the manufacturer’s instructions. This figure demonstrates the positive detection of HEV RNA with compatible strands 5 and 3. 1: Marker 100 bp (Promega); 2: White amplification; 3: Positive control for HEV RNA; 4: Negative control for HEV RNA; 5: Liver biopsy sample (HT370).

Figure 3 Evolution of aspartate aminotransferase and alanine aminotransferase until the 6th month after the hospitalization, with normalization soon after day 30, under no immunosuppression. AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.

and ASMA were within normal range, after more than 4 mo with no immunosuppression treatment (Figure 3 and Table 1). First day, the serum gamma globulin was 3.15 g/dL; 30 d, the serum gamma globulin was 3.0 g/dL; 90 d, 1.5 g/dL; 180 d, 1.4 g/dL. The serum gamma globulin levels evolved over time, with normal values 6 mo after the admission under no immunosuppression. The patient remained asymptomatic during the 6 mo follow up period.

**DISCUSSION**

In the clinical setting of an acute hepatitis, according to the IAIHG score, the positive serologies for ANA, ASMA, high immunoglobulin and a compatible liver histology added up to a score of 14 points, which suggests a probable diagnosis for AIH. Even without considering the 3 points given for the viral negativity, the score would still be suggestive of probable AIH. Our patient improved, both clinically and biochemically on immunosuppressive treatment. The positivity for thyroid auto-antibodies favored a diagnosis of autoimmune disease. However, the improvement could be coincident with a self-limited viral hepatitis with a gradual recovery course, considering that both AST and ALT values started to decrease before the therapy was started. Sporadic cases of HEV in non-endemic areas are rare[1]. The patient's history and previous health status were not suspicious for viral hepatitis E. There have been case reports on the effect of HEV in cirrhotic patients and false positive results of anti-HEV antibodies in patients with chronic liver disease of autoimmune etiology[2]. However, our patient had no evidence of liver cirrhosis. The presence of detectable viremia and positive liver molecular biology confirmed the diagnosis of hepatitis E infection. There are several relevant issues which arise because of this patient. Firstly, even in non-endemic areas, HEV must be considered in the differential diagnosis when approaching a patient with an acute hepatitis. Secondly, if a patient tests positive for IgM, it can be a false positive result and viremia and/or molecular liver histology...
and immunohistochemical testing should be performed. IgM and IgG titers and their evolution in serial analysis could also be used to determine the hepatitis time frame. Viremia is detectable for 4 mo and is better determined with real-time PCR techniques. Compared to single and nested gel-based RT-PCR, the various real-time PCR assays have a higher sensitivity, are less laborious, save time and are less prone to cross contamination. Thirdly, it is known that a minority of patients (3%-5%) with chronic AIH can present with low HEV viremias\(^9\), highlighting the possibility of HEV also being a trigger for the development of AIH. Also, one must consider the possibility of HEV inducing serological abnormalities such as hyperimmunoglobulinemia, possibly through polyclonal stimulation mimicking AIH\(^9\). The anti-DSDNA positivity in our patient, with no other criteria for systemic lupus erythematosis\(^9\), could be interpreted as a non-specific crossed reaction finding. Although we gave the diagnosis of a viral hepatitis E infection in our patient, follow up will be necessary to determine if the serological and histological findings were due to mechanisms of non-specific reactions to a viral infection or even a specific reaction to a specific HEV strain that could trigger AIH in the future. Also, reassessing serology and serum HEV RNA detection through RT-PCR could be of value to characterize this case as an acute episode with spontaneous virological clearance or evolution to chronic hepatitis E, as it is now well known that this can occur, although mainly in transplanted livers. Acute hepatitis E can evolve to hepatic failure and ribavirin in monotherapy use has been reported in some patients to avoid the need for liver transplantation. In the setting of chronic hepatitis E in liver transplanted patients, after failure of immunosuppression reduction, ribavirin monotherapy for a minimum period of 3 mo is advised in order to clear the virus, through mechanisms yet not fully understood\(^9\). Given the normalization of symptoms and laboratory parameters and considering the high cost of the serological and PCR techniques used at our institution, and also considering the high diagnostic accuracy of the tests used during work up, we did not reassess the HEV RNA determination at 6 mo. In 1991, hepatitis A was identified as a trigger for autoimmune chronic hepatitis type 1 in individuals with a familial history of AIH. Our patient was a case of HEV and had no familial history of autoimmune diseases. However, the authors elucidated the mechanism through which virus could trigger AIH, besides molecular mimicry. In this case, HEV induced a defect in suppressor-inducer T lymphocytes specific for the asialoglycoprotein receptor, a surface receptor of the hepatocyte, which increases in HAI and induces cell inflammation\(^10\).

In conclusion, HEV should be considered in the differential diagnosis of an acute hepatitis, even in patients with a possible diagnosis of AIH. Further studies are needed to understand the interaction between AIH presenting as acute hepatitis and viral hepatitis E infection.

**ACKNOWLEDGMENTS**

We thank all the co-workers with Carlos Cardoso, from the Joaquim Chaves Laboratories and the Department of Pathology of Hospital Santa Maria, Lisbon, for their contribution.

**REFERENCES**

1. Pina S, Buti M, Cotrina M, Piella J, Girones R. HEV identified in serum from humans with acute hepatitis and in sewage of animal origin in Spain. *J Hepatol* 2000; 33: 826-833 [PMID: 11097493 DOI: 10.1016/S0168-8278(00)80316-5]
2. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cançado EL, Chapman RW, Cooksley WG, Caza AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Büschenfelde KH, Zeniya M. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. *J Hepatol* 1999; 31: 929-938 [PMID: 10580593 DOI: 10.1016/S0168-8278(99)80297-9]
3. Hennes EM, Zeniya M, Caza AJ, Parés A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, Bianchi FB, Shibata M, Schramm C, Eisenmann de Torres B, Galle PR, McFarlane IG, Dienes HP, Lohse AW. Simplified criteria for the diagnosis of autoimmune hepatitis. *Hepatology* 2008; 48: 169-176 [PMID: 18537184 DOI: 10.1002/hep.22222]
4. Nagasaki F, Ueno Y, Kanno N, Okamoto H, Shimosegawa T. A case of acute hepatitis with positive autoantibodies who actually had hepatitis E virus infection. *Hepatol Res* 2005; 32: 134-137 [PMID: 15925136 DOI: 10.1016/j.jhepres.2005.03.017]
5. Nagasaki F, Ueno Y, Mano Y, Igarashi T, Yahagi K, NiitSUMa H, Okamoto H, Shimosegawa T. A patient with clinical features of acute hepatitis E viral infection and autoimmune hepatitis. *Tokohu J Exp Med* 2005; 206: 173-179 [PMID: 15988974]
6. Le Cann P, Tong MJ, Werneke J, Coursaget P. Detection of antibodies to hepatitis E virus in patients with autoimmune chronic active hepatitis and primary biliary cirrhosis. *Scand J Gastroenterol* 1997; 32: 387-389 [PMID: 9140163 DOI: 10.3109/0036552970900769]
7. Manns MP, Caza AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. *Hepatology* 2010; 51: 2193-2213 [PMID: 20513004 DOI: 10.1002/hep.23864]
8. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997; 40: 1725 [PMID: 9324032 DOI: 10.1002/art.1780400928]
9. Wedemeyer H, Pischke S, Manns MP. Pathogenesis and treatment of hepatitis e virus infection. *Gastroenterology* 2012; 142: 1388-1397.e1 [PMID: 22537448 DOI: 10.1053/j.gastro.2012.02.014]
10. Vento S, Garofano T, Di Perri G, Dolci L, Concia E, Bassetti D. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. *Lancet* 1991; 337: 1183-1187 [PMID: 1673738 DOI: 10.1016/0140-6736(91)92858-Y]